This activity is supported by an educational grant from Adapt Pharma.

Patrick Bridgeman, PharmD, BCPS
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Department of Pharmacy Practice and Administration
Clinical Pharmacy Specialist
Emergency Medicine
Robert Wood Johnson University Hospital
New Brunswick, New Jersey

Editorial Support
Jeannette Y. Wick, RPh, MBA, FASCP
Freelance Medical Writer
Arlington, Virginia
Visiting Professor
University of Connecticut School of Pharmacy
Storrs, Connecticut
Educational Objectives
After completing this continuing education program, the participant will be able to:
  1. Examine the prevalence of opioid overdose and its implications for society.
  2. Explore strategies and legislation aimed at reducing the growth of opioid-related overdoses and identify at-risk patients to ensure these strategies are aimed at the right audience.
  3. Explain the mechanism of action of naloxone, its role as an opiate antagonist, and its safety and efficacy profile.
  4. Distinguish the differences between the intravenous, intramuscular/subcutaneous, and intranasal routes of administration for naloxone.
  5. Illustrate the pharmacist’s role in educating patients about naloxone, including the role of the pharmacist in dispensing naloxone without a prescription.
Target audience: Retail Pharmacists
Type of activity: Application
Release date: March 7, 2016
Expiration date: March 7, 2017
Estimated time to complete activity: 2.0 hours
Fee: Free
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-020-H01-P. The activity is available for CE credit through March 7, 2018.